Axsome Therapeutics (NASDAQ:AXSM) Stock Gets Price Target Reduction from Robert W. Baird

Axsome Therapeutics (NASDAQ:AXSM) had its price target decreased by stock analysts at Robert W. Baird from $246.00 to $220.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird‘s target price indicates a potential upside of 61.75% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. UBS Group reiterated a “buy” rating and set a $239.00 price objective on shares of Axsome Therapeutics in a report on Tuesday. HC Wainwright restated a “buy” rating on shares of Axsome Therapeutics in a research note on Friday, September 25th. Zacks Research raised shares of Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Thursday, October 15th. Finally, BMO Capital Markets started coverage on Axsome Therapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $310.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $272.26.

Axsome Therapeutics Stock Performance

AXSM stock opened at $136.01 on Tuesday. The company has a quick ratio of 1.34, a current ratio of 1.43 and a debt-to-equity ratio of 1.52. The business’s fifty day simple moving average is $183.33 and its two-hundred day simple moving average is $198.74. Axsome Therapeutics has a twelve month low of $123.00 and a twelve month high of $260.19. The firm has a market cap of $7.12 billion, a price-to-earnings ratio of -36.27 and a beta of 0.86.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.38. The firm had revenue of $259.69 million during the quarter, compared to analyst estimates of $249.19 million. Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. The business’s revenue was up 51.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.94) earnings per share. Analysts predict that Axsome Therapeutics will post -3.04 earnings per share for the current year.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 45,004 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $212.01, for a total transaction of $9,541,298.04. Following the completion of the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $1,532,620.29. This represents a 86.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Mark L. Jacobson sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the completion of the sale, the chief operating officer owned 10,000 shares of the company’s stock, valued at approximately $2,086,500. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 59,664 shares of company stock worth $12,624,805. 20.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Privium Fund Management B.V. grew its stake in shares of Axsome Therapeutics by 7.5% during the third quarter. Privium Fund Management B.V. now owns 42,944 shares of the company’s stock worth $7,918,000 after acquiring an additional 3,000 shares during the last quarter. Commonwealth Equity Services LLC increased its holdings in shares of Axsome Therapeutics by 64.7% during the third quarter. Commonwealth Equity Services LLC now owns 4,019 shares of the company’s stock valued at $741,000 after acquiring an additional 1,579 shares in the last quarter. Factory Mutual Insurance Co. acquired a new position in shares of Axsome Therapeutics during the third quarter valued at about $323,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Axsome Therapeutics in the 3rd quarter valued at approximately $494,000. Finally, Profund Advisors LLC raised its position in shares of Axsome Therapeutics by 608.6% in the 3rd quarter. Profund Advisors LLC now owns 7,291 shares of the company’s stock valued at $1,344,000 after purchasing an additional 6,262 shares during the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Q3 results exceeded expectations: Axsome reported revenue of $259.7 million, up 51.9% year over year and ahead of the approximately $249.2 million consensus estimate. Its loss narrowed to $0.25 per share, versus analyst expectations for a loss of roughly $0.63 per share and a $0.94 loss in the prior-year quarter. Axsome Q3 earnings flash
• Positive Sentiment: Broad commercial and pipeline progress: Sales increased across key brands, while management highlighted additional pipeline milestones expected in 2027, supporting the longer-term growth outlook. Axsome Q3 sales and pipeline update
• Neutral Sentiment: Mixed earnings quality: Analysts noted that some of the quarter’s sales improvement reflected one-time items and better gross-to-net adjustments rather than fully sustainable prescription-volume growth. Axsome post-earnings analysis
• Negative Sentiment: Auvelity launch concerns dominate: The Alzheimer’s-care launch is reportedly progressing more slowly than hoped, with incremental growth coming primarily from depression prescriptions among patients under 65 rather than from the new Alzheimer’s indication. Those concerns have outweighed the Q3 beat and pushed AXSM toward fresh 52-week lows. AXSM Auvelity launch concerns
• Negative Sentiment: Analyst price targets were reduced: UBS lowered its target to $239 from $256, while Piper Sandler cut its target to $235 from $238, reflecting more cautious expectations for the launch and near-term growth. UBS lowers Axsome price target

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.